Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Oxycelanim** is a Belarusian bioresorbable medicated wound dressing supplied as a knitted cellulose wipe for topical and implantation use. It consists of oxidized cellulose containing immobilized **gentamicin** and the synthetic immunomodulatory peptide **thymogen**. Oxidized cellulose provides local hemostatic activity, while gentamicin supplies prolonged local aminoglycoside antibacterial activity through inhibition of bacterial protein synthesis and thymogen is intended to stimulate cellular and humoral immune responses. It is indicated for purulent-inflammatory diseases of the skin, soft tissues, and mucous membranes, including infected wounds, trophic ulcers, furuncles, abscesses, carbuncles, paraproctitis, thermal burns, phlegmons, hidradenitis, and lymphadenitis, and may be implanted to help prevent postoperative purulent-septic complications. The originating institute reports a Belarusian registration certificate, and published work describes the product as intended for clinical use and industrial production. ([apteka.103.by](https://apteka.103.by/oksicelanim-instruktsiya/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxycelanim.